Rockwell Medical Inc. (RMTI) Director Kenneth L. Holt Sells 8,075 Shares
Rockwell Medical Inc. (NASDAQ:RMTI) Director Kenneth L. Holt sold 8,075 shares of Rockwell Medical stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $6.81, for a total transaction of $54,990.75. Following the sale, the director now owns 46,858 shares of the company’s stock, valued at $319,102.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Rockwell Medical Inc. (NASDAQ:RMTI) opened at 6.71 on Wednesday. The stock’s market capitalization is $345.74 million. Rockwell Medical Inc. has a 52 week low of $5.47 and a 52 week high of $13.50. The stock’s 50 day moving average is $7.21 and its 200-day moving average is $7.80.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. Rockwell Medical had a negative net margin of 33.04% and a negative return on equity of 28.90%. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $13.86 million. During the same period in the prior year, the company earned ($0.05) EPS. Rockwell Medical’s quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts forecast that Rockwell Medical Inc. will post ($0.37) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/rockwell-medical-inc-rmti-director-kenneth-l-holt-sells-8075-shares.html
Several large investors have recently made changes to their positions in RMTI. Vanguard Group Inc. boosted its position in Rockwell Medical by 4.8% in the second quarter. Vanguard Group Inc. now owns 1,832,115 shares of the company’s stock valued at $13,870,000 after buying an additional 83,440 shares during the period. State Street Corp boosted its position in Rockwell Medical by 4.0% in the first quarter. State Street Corp now owns 858,425 shares of the company’s stock valued at $6,451,000 after buying an additional 33,175 shares during the period. Geode Capital Management LLC boosted its position in Rockwell Medical by 0.8% in the first quarter. Geode Capital Management LLC now owns 307,440 shares of the company’s stock valued at $2,308,000 after buying an additional 2,500 shares during the period. BlackRock Investment Management LLC boosted its position in Rockwell Medical by 5.0% in the second quarter. BlackRock Investment Management LLC now owns 192,817 shares of the company’s stock valued at $1,460,000 after buying an additional 9,250 shares during the period. Finally, Swiss National Bank boosted its position in Rockwell Medical by 6.4% in the second quarter. Swiss National Bank now owns 93,100 shares of the company’s stock valued at $705,000 after buying an additional 5,600 shares during the period. 21.72% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on the stock. BTIG Research assumed coverage on shares of Rockwell Medical in a research report on Friday, August 19th. They set a “buy” rating and a $12.00 price target for the company. Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.